Spots Global Cancer Trial Database for hedgehog inhibitor
Every month we try and update this database with for hedgehog inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC | NCT04155190 | Recurrent Basal... | Patidegib Topic... Patidegib Topic... | 18 Years - | Sol-Gel Technologies, Ltd. | |
| A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT01546038 | Acute Myeloid L... | PF-04449913 Low dose ARA-C ... PF-04449913 Decitabine PF-04449913 Daunorubicin Cytarabine PF-04449913 Daunorubicin Cytarabine PF-04449913 Low dose ARA-C ... | 18 Years - | Pfizer | |
| An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC | NCT04155190 | Recurrent Basal... | Patidegib Topic... Patidegib Topic... | 18 Years - | Sol-Gel Technologies, Ltd. | |
| A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT01546038 | Acute Myeloid L... | PF-04449913 Low dose ARA-C ... PF-04449913 Decitabine PF-04449913 Daunorubicin Cytarabine PF-04449913 Daunorubicin Cytarabine PF-04449913 Low dose ARA-C ... | 18 Years - | Pfizer | |
| A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations | NCT05199584 | Solid Tumors Wi... | ENV-101 (talade... | 18 Years - | Endeavor Biomedicines, Inc. | |
| Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas | NCT02828111 | Basal Cell Carc... | Patidegib Vehicle gel | 18 Years - 85 Years | PellePharm, Inc. | |
| Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas | NCT02828111 | Basal Cell Carc... | Patidegib Vehicle gel | 18 Years - 85 Years | PellePharm, Inc. | |
| A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia | NCT03416179 | Leukemia, Myelo... | glasdegib daunorubicin + ... azacitidine Placebo Placebo glasdegib cytarabine HSCT | 18 Years - | Pfizer | |
| Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma | NCT01431794 | Pancreatic Duct... | LDE225-600mg Gemcitabine nab-paclitaxel LDE225-400mg LDE225-800mg | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer | NCT01713218 | Pancreatic Aden... | gemcitabine Vismodegib Neoadjuvant che... | 18 Years - | Erasme University Hospital | |
| Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | NCT05538091 | Platinum-Resist... Platinum-Resist... PARP Inhibitor Hedgehog Inhibi... | Vismodegib Atezolizumab | 18 Years - | University of Pittsburgh |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
